Luteolin inhibits Porphyromonas gingivalis growth and alleviates alveolar bone destruction in experimental murine periodontitis

Biosci Biotechnol Biochem. 2023 Dec 19;88(1):37-43. doi: 10.1093/bbb/zbad137.

Abstract

Periodontal disease is a major oral infectious disease that destroys alveolar bones and causes tooth loss. Porphyromonas gingivalis is a key pathogen that plays a crucial role in periodontitis. In our previous study on the anti-P. gingivalis activity of flavonoid, luteolin, a major flavonoid in edible plants, inhibited the proteolytic activity of gingipains, the major virulence factor in P. gingivalis. This study demonstrated luteolin in vitro and in vivo anti-bacterial activities. Thus, luteolin inhibits planktonic growth and biofilm formation in P. gingivalis. Furthermore, oral administration of luteolin alleviated maxillary alveolar bone resorption (ABR) in murine periodontitis induced by P. gingivalis infection. These results indicate that luteolin may be a potential therapeutic compound that targets P. gingivalis by hindering its growth, biofilm formation, and ABR in the oral cavity.

Keywords: Porphyromonas gingivalis; alveolar bone resorption; luteolin; periodontitis.

MeSH terms

  • Alveolar Bone Loss* / drug therapy
  • Alveolar Bone Loss* / microbiology
  • Animals
  • Disease Models, Animal
  • Luteolin / pharmacology
  • Luteolin / therapeutic use
  • Mice
  • Periodontitis* / drug therapy
  • Periodontitis* / microbiology
  • Porphyromonas gingivalis

Substances

  • Luteolin